Aurinia Pharmaceuticals (NASDAQ:AUPH) Research Coverage Started at Oppenheimer

Share on StockTwits

Oppenheimer initiated coverage on shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) in a research report report published on Tuesday, BenzingaRatingsTable reports. The brokerage issued an outperform rating and a $14.00 price objective on the biotechnology company’s stock.

AUPH has been the topic of several other research reports. Royal Bank of Canada restated a buy rating and issued a $11.00 target price on shares of Aurinia Pharmaceuticals in a report on Thursday, August 8th. BidaskClub cut shares of Aurinia Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, September 5th. Citigroup assumed coverage on shares of Aurinia Pharmaceuticals in a report on Monday. They issued an outperform rating and a $14.00 target price on the stock. Zacks Investment Research cut shares of Aurinia Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, July 16th. Finally, HC Wainwright restated a buy rating and issued a $25.00 target price on shares of Aurinia Pharmaceuticals in a report on Tuesday, June 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $15.18.

Shares of AUPH opened at $6.45 on Tuesday. The firm’s 50 day simple moving average is $5.92 and its 200 day simple moving average is $6.29. The company has a market capitalization of $600.57 million, a P/E ratio of -8.49 and a beta of 1.12. Aurinia Pharmaceuticals has a 1-year low of $5.06 and a 1-year high of $7.85.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). Aurinia Pharmaceuticals had a negative net margin of 13,231.97% and a negative return on equity of 50.08%. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.05 million. As a group, research analysts anticipate that Aurinia Pharmaceuticals will post -0.68 EPS for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Victory Capital Management Inc. purchased a new position in shares of Aurinia Pharmaceuticals in the 1st quarter worth about $45,000. Toronto Dominion Bank raised its position in shares of Aurinia Pharmaceuticals by 64.7% in the 1st quarter. Toronto Dominion Bank now owns 9,780 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 3,842 shares during the last quarter. Spark Investment Management LLC purchased a new position in shares of Aurinia Pharmaceuticals in the 1st quarter worth about $71,000. UBS Asset Management Americas Inc. bought a new stake in Aurinia Pharmaceuticals in the 2nd quarter worth about $88,000. Finally, A.R.T. Advisors LLC increased its holdings in Aurinia Pharmaceuticals by 44.9% in the 2nd quarter. A.R.T. Advisors LLC now owns 18,395 shares of the biotechnology company’s stock worth $121,000 after buying an additional 5,700 shares in the last quarter. 31.96% of the stock is owned by hedge funds and other institutional investors.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

See Also: How can you know how many shares are floating?

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.